Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9,814
  • Shares Outstanding, K 381,882
  • Annual Sales, $ 5,520 K
  • Annual Income, $ -3,480 K
  • 36-Month Beta 6.04
  • Price/Sales 1.51
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0152 +69.08%
on 01/16/19
0.0280 -8.21%
on 02/13/19
+0.0077 (+42.78%)
since 01/15/19
3-Month
0.0106 +142.45%
on 12/26/18
0.0280 -8.21%
on 02/13/19
+0.0041 (+18.98%)
since 11/15/18
52-Week
0.0106 +142.45%
on 12/26/18
0.0880 -70.80%
on 04/09/18
-0.0162 (-38.66%)
since 02/15/18

Most Recent Stories

More News
USRM Chief Science Officer Featured on One Radio Network

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer has...

USRM : 0.0257 (+9.83%)
USRM Chief Science Officer Featured on One Radio Network

SUNRISE, Fla. , Jan. 15, 2019 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0257 (+9.83%)
Dr. Kristin Comella Featured on Robert Scott Bell Show

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0257 (+9.83%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced third quarter results for this...

USRM : 0.0257 (+9.83%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

SUNRISE, Fla. , Nov. 7, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0257 (+9.83%)
Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers

SUNRISE, Fla. , Oct. 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0257 (+9.83%)
World Bodybuilding Expert Interviews USRM Chief Science Officer At Paleo F(X) Conference

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the release of USRM Chief Science...

USRM : 0.0257 (+9.83%)
USRM Chief Science Officer, Dr. Kristin Comella, Featured on Health Boot Camps' Webinar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer,...

USRM : 0.0257 (+9.83%)
U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0257 (+9.83%)
U.S. Stem Cell Reports First Quarter Results

SUNRISE, Fla. , May 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0257 (+9.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade USRM with:

Key Turning Points

2nd Resistance Point 0.0284
1st Resistance Point 0.0271
Last Price 0.0257
1st Support Level 0.0230
2nd Support Level 0.0202

See More

52-Week High 0.0880
Fibonacci 61.8% 0.0584
Fibonacci 50% 0.0493
Fibonacci 38.2% 0.0402
Last Price 0.0257
52-Week Low 0.0106

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar